1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Cronos Group Inc.
  6. Summary
    CRON   CA22717L1013

CRONOS GROUP INC.

(CRON)
  Report
Delayed Toronto Stock Exchange  -  04:00 2022-06-30 pm EDT
3.600 CAD   -2.44%
06/28Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster Absorption
AQ
06/27Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders
AQ
06/27Cronos Group Says to Use Geocann's VESIsorb Delivery Technology for Cannabinoid Products
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
06/24/2022 06/27/2022 06/28/2022 06/29/2022 06/30/2022 Date
4.03(c) 3.98(c) 3.91(c) 3.69(c) 3.6(c) Last
347 663 266 153 215 897 199 661 343 661 Volume
+4.68% -1.24% -1.76% -5.63% -2.44% Change
More quotes
Estimated financial data (e)
Sales 2022 150 M 116 M 116 M
Net income 2022 -134 M -104 M -104 M
Net cash position 2022 1 215 M 941 M 941 M
P/E ratio 2022 -10,8x
Yield 2022 -
Sales 2023 208 M 161 M 161 M
Net income 2023 -97,9 M -75,8 M -75,8 M
Net cash position 2023 1 180 M 913 M 913 M
P/E ratio 2023 -13,1x
Yield 2023 -
Capitalization 1 352 M 1 047 M 1 047 M
EV / Sales 2022 0,92x
EV / Sales 2023 0,83x
Nbr of Employees 626
Free-Float 52,1%
More Financials
Company
Cronos Group Inc. is a cannabinoid company. The Company is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones, Happy Dance and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones, Happy Dance and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of Cronos Group Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about CRONOS GROUP INC.
06/28Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster ..
AQ
06/27Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders
AQ
06/27Cronos Group Says to Use Geocann's VESIsorb Delivery Technology for Cannabinoid Product..
MT
06/27CRONOS GROUP BRIEF : Partners with Geocann to Leverage VESIsorb Delivery Technology for Fa..
MT
06/27Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster..
GL
06/27Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster..
GL
06/24CRONOS GROUP INC. : Submission of Matters to a Vote of Security Holders, Financial Stateme..
AQ
06/24Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders
GL
06/24Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders
AQ
06/24CRONOS : Announces Results of 2022 Annual Meeting of Shareholders - Form 8-K
PU
06/21Cronos Group and NYSE's Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
MT
06/21CRONOS GROUP BRIEF : Says It and NYSE's Ginkgo Bioworks Announce Achievement of THCV Equit..
MT
06/21Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
PR
06/21Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
GL
06/15TSX gets boost from miners ahead of Fed decision
RE
More news
News in other languages on CRONOS GROUP INC.
06/14BOLSA DE MADRID : Los osos son liberados
06/14Les ours sont lâchés
05/27Aurora Cannabis augmente son financement par prise ferme ; baisse de 39,5 %.
05/10Cronos Group en hausse de 1,1 % avant le marché alors que sa perte du premier trimestre..
05/10Earnings Flash (CRON.TO) Le GROUPE CRONOS déclare une perte nette de 32,6523 millions d..
More news
Analyst Recommendations on CRONOS GROUP INC.
More recommendations
Chart CRONOS GROUP INC.
Duration : Period :
Cronos Group Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRONOS GROUP INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3,60 CAD
Average target price 6,21 CAD
Spread / Average Target 72,5%
EPS Revisions
Managers and Directors
Michael Ryan Gorenstein Chairman, President & Chief Executive Officer
Robert L. Madore Chief Financial Officer
Arye Weigensberg Vice President-Research & Technology
Jason Marc Adler Independent Director
James D. Rudyk Lead Independent Director